Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Clinical Trial
Official title:
REal-world Patterns of Treatment With CDKi 4/6 for AdVanced BrEast CAncer in PortugaL - REVEAL Study
This was a non-interventional (observational), retrospective, cohort study of women with hormone receptor (HR)-positive and human epidermal growth factor receptor-type 2 (HER2)-negative advanced breast cancer who started treatment with cyclin-dependent kinase inhibitors (CDKi) 4/6 (ribociclib or palbociclib) in Portugal. This was a study of medication use patterns, based on information from the hospital pharmacies of the participating centers. Patients who started a CDKi 4/6 (ribociclib or palbociclib) between 1 March 2019 and 31 December 2019 were included and followed through 24 months. A follow-up occurred 6 months after the start of CDKi 4/6 (ribociclib or palbociclib) to quantify the occurrence of dose changes.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02894398 -
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
|
Phase 2 | |
| Recruiting |
NCT02175446 -
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
|
Phase 2 | |
| Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01885013 -
Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients
|
Phase 2 | |
| Completed |
NCT01935492 -
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05735080 -
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02668666 -
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
| Terminated |
NCT02823262 -
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
|
N/A | |
| Completed |
NCT02806817 -
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
|
Early Phase 1 | |
| Terminated |
NCT02824575 -
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
|
Phase 1 | |
| Terminated |
NCT01394211 -
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06348134 -
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
|
Phase 2 | |
| Not yet recruiting |
NCT06338644 -
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
|
||
| Not yet recruiting |
NCT01779531 -
Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients
|
N/A | |
| Completed |
NCT01288261 -
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT03285568 -
Patterns of Prescribing and Monitoring of Palbociclib
|
||
| Active, not recruiting |
NCT02623972 -
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
| Terminated |
NCT01905592 -
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
|
Phase 3 | |
| Recruiting |
NCT06264921 -
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT03854617 -
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 2 |